Two distinct target sites on IMP dehydrogenase in chemotherapy.
Yamada
Y
Y
Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46223.
Natsumeda
Y
Y
Yamaji
Y
Y
Weber
G
G
D000227:Adenine Nucleotides / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004357:Drug Synergism; D006157:Guanosine Monophosphate / Q000096:biosynthesis; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007291:Inosine Monophosphate / Q000378:metabolism; D007658:Ketone Oxidoreductases / Q000037:antagonists & inhibitors*; D008114:Liver Neoplasms, Experimental / Q000201:enzymology*; D009243:NAD / Q000378:metabolism; D009711:Nucleotides / Q000494:pharmacology*; D051381:Rats; D012265:Ribonucleotides / Q000378:metabolism / Q000494:pharmacology*; D013696:Temperature; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D019820:Xanthine
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D009711:Nucleotides; D012265:Ribonucleotides; D009243:NAD; D007291:Inosine Monophosphate; D019820:Xanthine; C009174:ribavirin-5'-phosphate; C011141:xanthosine monophosphate; C062485:bredinin 5'-monophosphate; C038167:thiazole-4-carboxamide adenine dinucleotide; D006157:Guanosine Monophosphate; D007168:IMP Dehydrogenase; D007658:Ketone Oxidoreductases